Moreover, validated PKG targets like CREB and CaMKs merit exploration as novel (surrogate) biomarkers to determine the effects of a clinical PKG-targeted treatment for IRDs. The gene discussed is CREB1; the disease is respiratory distress syndrome in premature infants.